Possibilities of enhancing the neuroprotective effect of autophagy activation in the brain by stimulation of an mTOR-independent pathway of its regulation in a transgenic mouse model of Parkinson’s disease

Akopyan A.A.1, Pupyshev A. B2, Tikhonova M.A.31Scientific Research Institute of Physiology and Basic Medicine Novosibirsk, Russia, annaaleksanovna@mail.ru2Scientific Research Institute of Physiology and Basic Medicine Novosibirsk, Russia, apupyshev@mail.ru3Scientific Research Institute of Physiology and Basic Medicine Novosibirsk, Russia, mar-a-tikh@mail.ru Autophagy induction promotes cell survival that is especially important for neurons which have a limited proliferative resource. Autophagy is regulated by the classical mTOR-dependent mechanism activated by rapamycin, and also via mTOR-independent pathways triggered by trehalose, lithium, metformin, etc. The neuroprotective effect was shown upon combined activation of these pathways in vitro. However, the possibilities of enhancing the therapeutic effect of autophagy activation in vivo remain unclear. Transgenic mice of B6.Cg-Tg (Prnp-SNCA*A53T)23Mkle/J strain with overexpression of alpha-synuclein were used as a model of Parkinson’s disease (PD) in the study. In the striatum and substantia nigra, which are mainly affected in PD, trehalose caused an increase in autophagy, as measured by the expression of the autophagy marker LC3-II. Trehalose in combination with rapamycin increased LC3-II expression by two to three times in comparison with the action of rapamycin alone. In the frontal cortex no changes in LC3-II expression were observed neither under the action of trehalose nor with the combined treatment with trehalose and rapamycin. The most pronounced neuroprotective effect was observed upon the combined use of rapamycin and trehalose by the tyrosine hydroxylase expression in the nigrostriatal system marking the restoration of dopaminergic neurons. In the Rotarod test, the mice were tested for motor function. Animals treated with rapamycin, trehalose, or their combination stayed much longer on a rotating drum, compared to controls. Autophagy contribution to the therapeutic effects was confirmed by administration of autophagy inhibitor 3-methyladenine, which completely blocks the neuroprotective effects of the drugs. Acknowledgments This work was supported  by a grant No. 16-04-01423 from the Russian Foundation for Basic Research.

Read More

Genome-wide association study of Parkinson’s disease using MAX3 test

Poster (download) Georgii Ozhegov1, Dmitry Poverin2, Sergey Medvedev3, Suren Zakian4, Yuri Vyatkin5, Sergey Postovalov6 1Kazan Federal University, Kazan, Russia; Novel Software Systems, Ltd., Novosibirsk, Russia, georgii_provisor@mail.ru 2Novosibirsk State Technical University, Novosibirsk, Russia, foxlandg@gmail.com 3Federal Research Center Institute of Cytology and Genetics, Novosibirsk, Russia, medvedev@bionet.nsc.ru 4Federal Research Center Institute of Cytology and Genetics, Novosibirsk, Russia, zakian@bionet.nsc.ru 5Novosibirsk State University, Novosibirsk, Russia; Novel Software Systems, Ltd., Novosibirsk, Russia, yuri@nprog.ru 6Novosibirsk State Technical University, Novosibirsk, Russia; Novosibirsk State University, Novosibirsk, Russia, postovalovsn@gmail.com Whole exomes for a set of patients with Parkinson’s disease (PD) were sequenced to conduct a genome-wide association study (GWAS) using MAX3 test to find novel genomic variants associated with the disease. As a result, several new variants were identified.

Read More